“Ridding the Race of His Defective Blood”—Eugenics in the Journal, 1906–1948
By Paul A. Lombardo,
The New England Journal of Medicine
| 03. 02. 2024
In 1923, Boston City Hospital chose Dr. William Mayo, already famous for the work of his Minnesota clinic, to speak at the inauguration of a new laboratory. Mayo’s thoughts on hospital administration, published in the Boston Medical and Surgical Journal (which would be renamed the New England Journal of Medicine in 1928), highlighted the common anxieties of his profession and went far beyond the anodyne comments that were usual on such occasions.1 Mayo amplified the phobias and fed the moral panic stemming from the eugenic thought of that time, saying that municipal hospitals were swamped by the poor, as cities were besieged by criminals and the country threatened with demise by waves of defective immigrants. While Congress debated increased restriction on immigration, Mayo traced poverty to “constitutional inferiority and mental instability,” declaring both “to a large extent hereditary.”
Mayo said one goal of public hospitals should be to “reduce the number of people whom it must care for at the expense of the taxpayer.” A robust sterilization program and limits on immigration of the “defective” would serve that goal...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...